Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough - 18/11/20
páginas | 13 |
Iconografías | 3 |
Vídeos | 0 |
Otros | 0 |
Graphical abstract |
Highlights |
• | Modest efficacy, toxicity, and poor effectiveness against brain metastasis are common limitations of multi-targeted novel molecular inhibitors. |
• | A promising prospect was shown recently in selective RET inhibitors. |
• | The development of multitarget agents and specific inhibitors has been evaluated in clinical trials. |
• | More studies need to be conducted on the targeted therapies against RET arrangement cancer. |
Abstract |
Genomic profiling has revolutionized treatment options for patients with oncogene-driven cancers, such as epidermal growth factor receptor (EGFR) mutant carcinoma. Rearranged during transfection (RET) rearrangement, as one of the main activated oncogenes, has been well studied and found to be involved in the malignant behavior of carcinogenesis, resulting in acquired resistance to EGFR tyrosine kinase inhibitors and inducing an intrinsic resistance to immunotherapy. Thus, targeted therapies have been investigated against RET arrangement cancers, including several multi-kinase inhibitors and selective RET inhibitors. However, modest efficacy, a relatively high rate of toxicity, and poor effectiveness against brain metastasis are common limitations of multi-targeted novel molecular inhibitors. A promising prospect was shown recently in selective RET inhibitors in several ongoing clinical trials. In this review, we reviewed the concurrent dilemmas of targeted therapies against RET arrangement cancer from preclinical and clinical studies and proposed several clinical considerations for clinical practice prospectively.
El texto completo de este artículo está disponible en PDF.Abbreviations : RET, EGFR, ALK, ROS1, BRAF, RTK, TKI, NCCN, KRAS, PD-L1, MET, HER2, CCDC6, NCOA4, KIF5B, ASCO, FDA, MEN2A, ATC, DTC, RR-DTC, FTC, MTC, PTC, NSCLC, CNS, NA, NR, ORR, mDOR, mOS, mPFS, AE, TEAE, TTP, PAS, VEGFR, AXL, c-KIT, FLT3, TIE2, FGFR, PDGFRA, PDGFRB, LTK, CHEK2, BCR-ABL, SRC, NTRK, DDR, CBR, QOL, AUC, Cmax
Keywords : RET, Targeted therapy, Oncogene, Drug resistance
Esquema
Vol 132
Artículo 110901- décembre 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?